These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of subthalamic nucleus stimulation and L-dopa in trunk kinematics of patients with Parkinson's disease. Ferrarin M; Rizzone M; Lopiano L; Recalcati M; Pedotti A Gait Posture; 2004 Apr; 19(2):164-71. PubMed ID: 15013505 [TBL] [Abstract][Full Text] [Related]
8. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine]. Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547 [TBL] [Abstract][Full Text] [Related]
9. Restoration of normal motor control in Parkinson's disease during REM sleep. De Cock VC; Vidailhet M; Leu S; Texeira A; Apartis E; Elbaz A; Roze E; Willer JC; Derenne JP; Agid Y; Arnulf I Brain; 2007 Feb; 130(Pt 2):450-6. PubMed ID: 17235126 [TBL] [Abstract][Full Text] [Related]
10. Growth hormone response to L-dopa in the thinned obese. Laurian L; Oberman Z; Hoerer E; Wiznitzer T; Harell A Isr J Med Sci; 1982 May; 18(5):625-9. PubMed ID: 7096047 [TBL] [Abstract][Full Text] [Related]
11. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Garcia-Borreguero D; Larrosa O; Granizo JJ; de la Llave Y; Hening WA Sleep; 2004 Jun; 27(4):669-73. PubMed ID: 15283001 [TBL] [Abstract][Full Text] [Related]
12. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Tan A; Salgado M; Fahn S Mov Disord; 1996 Mar; 11(2):214-6. PubMed ID: 8684394 [TBL] [Abstract][Full Text] [Related]
13. Dementia and treatment with L-dopa in Parkinson's disease. Hietanen M; Teräväinen H Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964 [TBL] [Abstract][Full Text] [Related]
14. Effects of levodopa on nocturnal penile tumescence: a preliminary study. Horita H; Sato Y; Adachi H; Suzuki N; Kato R; Hisasue S; Suzuki K; Tsukamoto T J Androl; 1998; 19(5):619-24. PubMed ID: 9796623 [TBL] [Abstract][Full Text] [Related]
15. Nocturnal cardiac autonomic regulation in Parkinson's disease. Kallio M; Suominen K; Haapaniemi T; Sotaniemi K; Myllylä VV; Astafiev S; Tolonen U Clin Auton Res; 2004 Apr; 14(2):119-24. PubMed ID: 15095055 [TBL] [Abstract][Full Text] [Related]
16. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients. Hansen AP; Christensen SE; Lundbaek K Scand J Clin Lab Invest; 1975 May; 35(3):205-10. PubMed ID: 1153917 [TBL] [Abstract][Full Text] [Related]
17. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Merello M; Nouzeilles MI; Arce GP; Leiguarda R Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878 [TBL] [Abstract][Full Text] [Related]
18. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Schneider HJ; Oertel H; Murck H; Pollmächer T; Stalla GK; Steiger A Psychoneuroendocrinology; 2005 Jan; 30(1):29-37. PubMed ID: 15358440 [TBL] [Abstract][Full Text] [Related]
19. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol]. Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031 [TBL] [Abstract][Full Text] [Related]
20. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]